Financial Performance - Revenue for the year ended December 31, 2025, was RMB 1,471,013 thousand, a slight increase of 2.0% from RMB 1,442,292 thousand in the previous year[5] - Gross profit decreased to RMB 267,619 thousand, down 2.8% from RMB 275,819 thousand year-on-year[5] - Net profit for the year was RMB 139,029 thousand, significantly up from RMB 26,329 thousand in the previous year, marking a growth of 427.5%[6] - Adjusted net profit was RMB 121,152 thousand, down 14.0% from RMB 141,924 thousand in the previous year[5] - Basic earnings per share improved to RMB 1.00, compared to a loss of RMB 0.19 in the previous year[6] - Total comprehensive income for the year was RMB 178,281 thousand, compared to a loss of RMB 4,285 thousand in the previous year[7] - EBITDA for 2025 was RMB 183,632,000, compared to RMB 244,968,000 in 2024, indicating a decrease of about 25.0%[25] - Net profit for the year was approximately RMB 139.0 million, an increase of about RMB 112.7 million compared to RMB 26.3 million in the previous year, mainly due to increased convertible bond income[51] Assets and Liabilities - Non-current assets totaled RMB 1,478,095 thousand, slightly down from RMB 1,484,046 thousand in the previous year[8] - Current assets decreased to RMB 1,098,766 thousand from RMB 1,099,116 thousand year-on-year[8] - Total liabilities decreased to RMB 1,177,630 thousand from RMB 1,196,614 thousand in the previous year[9] - Total equity increased to RMB 720,828 thousand from RMB 576,623 thousand year-on-year, reflecting a growth of 25.0%[9] - The total assets as of December 31, 2025, amounted to RMB 2,576,861,000, slightly down from RMB 2,583,162,000 in 2024[25] - The company’s total liabilities decreased to RMB 1,856,033,000 in 2025 from RMB 2,006,539,000 in 2024, a reduction of approximately 7.5%[25] - As of December 31, 2025, current assets were approximately RMB 1,098.8 million, while current liabilities were approximately RMB 678.4 million, resulting in a current ratio of approximately 1.62[52] Revenue Segments - The company has three reportable segments: Comprehensive Hospital Services, Hospital Management Services, and Pharmaceutical Sales, each contributing to overall revenue[18][19][20] - Comprehensive hospital services revenue rose by about 8.2% from RMB 1,303.4 million in 2024 to RMB 1,410.7 million in 2025, primarily due to the consolidation of Cixi operations[46] - Hospital management services revenue decreased by approximately 61.7% from RMB 124.1 million in 2024 to RMB 47.5 million in 2025, mainly due to reduced services provided to managed hospitals[47] Expenses - Total costs increased by approximately 3.2% from RMB 1,166.5 million in 2024 to RMB 1,203.4 million in 2025, attributed to business consolidation[48] - Administrative expenses rose by approximately 11.2% from RMB 109.0 million in 2024 to RMB 121.2 million in 2025, also due to business consolidation[49] - Employee benefits expenses for the year ended December 31, 2025, amounted to approximately RMB 490.1 million, an increase from RMB 446.7 million in 2024[64] Accounting Policies and Compliance - The company adopted a new accounting policy, changing its functional currency from RMB to HKD effective January 1, 2025, due to operational transactions being primarily in HKD[16] - The financial statements are prepared in accordance with International Financial Reporting Standards and comply with the Hong Kong Companies Ordinance[12] - An audit committee has been established, consisting of three independent non-executive directors, to review the financial statements for the year ending December 31, 2025, ensuring compliance with applicable accounting standards and regulations[70] - The financial data in the preliminary performance announcement has been agreed upon by the auditors, KPMG, and aligns with the audited financial statements for the year[71] Corporate Governance - The company has appointed Mr. Chen as the Chairman and acting CEO following the resignation of the previous CEO and Chairman on June 23, 2020, to ensure normal operations during the transition[68] - The company confirms that all directors have complied with the standard code of conduct for securities trading for the full year ending December 31, 2025[69] Future Plans and Investments - The company plans to initiate an innovation transformation action plan in 2026, focusing on patient-centered services and technology empowerment[44] - The group aims to enhance operational efficiency through investments in information technology and supply chain management, establishing a digital transformation infrastructure[44] - As of December 31, 2025, the company has no significant investments or future plans related to major investments or capital assets[59] Dividends and Shareholder Returns - The company did not declare any dividends for the fiscal year ending December 31, 2025, consistent with the previous year[39] - The company did not recommend a final dividend for the year ended December 31, 2025[63] Debt and Financing - The maturity date of the convertible bonds issued to Yufeng, amounting to HKD 468.0 million, has been extended from September 30, 2025, to September 30, 2027[55] - The maturity date of the convertible bonds issued to Hony Fund VIII, amounting to approximately HKD 773.9 million, has also been extended from September 30, 2025, to September 30, 2027[56] - Total borrowings decreased from RMB 82.1 million in 2024 to RMB 69.0 million in 2025, with a decrease in the interest-bearing debt ratio from 3.2% to 2.7%[52] Risk Management - The company faces foreign exchange risks primarily related to USD and HKD transactions, with no hedging instruments currently in use[60] - As of December 31, 2025, the company provided guarantees for loans totaling RMB 173.0 million and RMB 104.0 million for Jinhua Guangfu Hospital[61] Securities Transactions - There were no purchases, sales, or redemptions of the company's listed securities during the review year[65]
弘和仁爱医疗(03869) - 2025 - 年度业绩